|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:nitrosourea
gptkb:antibiotic
antineoplastic agent
|
|
gptkbp:approvalYear
|
1982
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XC03
|
|
gptkbp:CASNumber
|
18883-66-4
|
|
gptkbp:category
|
gptkb:antibiotic
antineoplastic and immunomodulating agent
|
|
gptkbp:chemicalFormula
|
C8H15N3O7
|
|
gptkbp:discoveredBy
|
gptkb:Upjohn_Company
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
streptozotocin
|
|
gptkbp:IUPACName
|
gptkb:2-deoxy-2-({[(methylnitrosoamino)carbonyl]amino})-D-glucopyranose
|
|
gptkbp:KEGGID
|
D00432
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
DNA alkylation
beta cell toxicity
|
|
gptkbp:meltingPoint
|
178–179 °C
|
|
gptkbp:MeSH_ID
|
gptkb:D013291
|
|
gptkbp:molecularWeight
|
265.22 g/mol
|
|
gptkbp:origin
|
gptkb:Streptomyces_achromogenes
|
|
gptkbp:produces_effect
|
insulin deficiency
hyperglycemia
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL156
gptkb:DB00628
29327
|
|
gptkbp:riskFactor
|
carcinogenicity
mutagenicity
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
hepatotoxicity
renal toxicity
|
|
gptkbp:solubility
|
water soluble
|
|
gptkbp:studiedBy
|
beta cell destruction
diabetes mellitus models
|
|
gptkbp:synonym
|
gptkb:STZ
gptkb:Zanosar
|
|
gptkbp:UNII
|
P28FDM1D8P
|
|
gptkbp:usedFor
|
induction of diabetes in experimental animals
treatment of pancreatic cancer
|
|
gptkbp:bfsParent
|
gptkb:multidrug_resistance-associated_protein_1
|
|
gptkbp:bfsLayer
|
6
|